Results 141 to 150 of about 1,185,623 (252)

Molecular mechanisms underlying the effectiveness of triiodothyroacetic acid (Triac) in patients with resistance to thyroid hormone β (RTHβ): a multicentre, international, retrospective cohort study. [PDF]

EBioMedicine
Liao W, Marelli F, Moran C, Campi I, Groeneweg S, Mohamed Z, Kamaleldeen E, Padidela R, Olivius C, Oosterkamp L, Leeuwenburgh S, Lyons G, Peeters RP, Chatterjee K, Persani L, Meima M, Visser WE.   +16 more
europepmc   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Endocrine and cardiovascular consequences of plasticiser exposure: a narrative review from the thyroid- cardiac axis perspective. [PDF]

Front Pharmacol
Halder D, P V V, Mitra T, Karthikeyan D, Anil Kumar AHS, S N MS, Mishra S, Janardhanan R.   +7 more
europepmc   +1 more source

Impact of Single‐Cell RNA Reference Selection for the Deconvolution of Breast Cancer Spatial Transcriptomics Datasets

International Journal of Cancer, EarlyView.
ABSTRACT Spot‐based spatial transcriptomics (ST) allows for unbiased gene expression analysis within tissue architecture, overcoming the limitations of single‐cell RNA sequencing (scRNA‐seq) by preserving spatial context. However, the high spatial resolution in ST leads to cellular heterogeneity within spots, requiring computational deconvolution to ...
Stefan Altendorfer, Scott J. Walker, Carsten O. Daub   +2 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth, Bruce Robinson, Valentina Boni, Daniel S.W. Tan, Caroline McCoach, Erminia Massarelli, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Vivek Subbiah   +10 more
wiley   +1 more source

Endocrine meets hepatic: the thyroid-liver axis in health and disease-an overview. [PDF]

Wien Med Wochenschr
Abdelsamad H, Mikosch P.
europepmc   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka, Johann Kornowski, Elena Laakmann, Barbara Schmalfeldt, Tim Zell, Glenn Geidel, Christoffer Gebhardt, Pia Roser, Volkmar Müller, Julian Kött   +9 more
wiley   +1 more source

Nutrition, thyroid function, and tuberculosis: exploring the endocrine-immune axis. [PDF]

Front Tuberc
Khachatourian N, Takhmazian R, Venketaraman V.   +2 more
europepmc   +1 more source

Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses

International Journal of Cancer, EarlyView.
ABSTRACT Medication taken for other reasons than for the treatment of malignant disease, termed concomitant medication, is known to affect outcomes when used with immune checkpoint inhibitor therapy and other oncological drugs. However, no research in humans has addressed the relationship between concomitant medications and efficacy of oncolytic ...
Santeri A. Pakola, Tatiana V. Kudling, Nea Ojala, James H. A. Clubb, Victor Arias, Elise Jirovec, Mirte van der Heijden, Arianna Eleuteri, Lyna Haybout, Susanna Grönberg‐Vähä‐Koskela, Katriina Jalkanen, Tuomo Alanko, Matthew S. Block, Inge Marie Svane, Anna Kanerva, Otto Hemminki, Dafne C. A. Quixabeira, Claudia Kistler, Suvi Sorsa, Victor Cervera‐Carrascon, Akseli Hemminki   +20 more
wiley   +1 more source

Resistance to thyroid hormone alpha associated with a novel THRA ligand-binding domain variant: familial clinical, biochemical, skeletal, and exploratory cerebral FDG-PET/CT metabolic findings. [PDF]

Front Endocrinol (Lausanne)
Mata-Salgado D, Morales-Suárez JJ, Reza-Albarrán AA, Hernández-Ramírez R, Corza-Ayala MA, Cienfuegos-Alvear JA, González-Jaimes AM, Martínez-Duncker I, Alaez-Verson C.   +8 more
europepmc   +1 more source